These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38019511)

  • 1. Aneurysm and Artery Dissection After Oral VEGFR-TKI Use in Adults With Cancer.
    Kang S; Yeon B; Kim MS; Yoo M; Kim B; Yu YM
    JAMA Netw Open; 2023 Nov; 6(11):e2345977. PubMed ID: 38019511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
    Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
    Lee N; Lee JL; Lee JY
    Target Oncol; 2023 Mar; 18(2):247-255. PubMed ID: 36826462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis.
    Das A; Mahapatra S; Bandyopadhyay D; Samanta S; Chakraborty S; Philpotts LL; Jahangir E; Roy B
    Crit Rev Oncol Hematol; 2021 Jan; 157():103186. PubMed ID: 33309571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis.
    Chen YC; Chen JH; Hsieh FI
    J Chin Med Assoc; 2024 Jan; 87(1):48-57. PubMed ID: 37991373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Qi WX; Sun YJ; Tang LN; Shen Z; Yao Y
    Crit Rev Oncol Hematol; 2014 Mar; 89(3):394-403. PubMed ID: 24182420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using a zebrafish xenograft tumor model to compare the efficacy and safety of VEGFR-TKIs.
    Wanting H; Jian Z; Chaoxin X; Cheng Y; Chengjian Z; Lin Z; Dan C
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5975-5987. PubMed ID: 36609710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Fluoroquinolone Use With Short-term Risk of Development of Aortic Aneurysm.
    Newton ER; Akerman AW; Strassle PD; Kibbe MR
    JAMA Surg; 2021 Mar; 156(3):264-272. PubMed ID: 33404647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular Endothelial Growth Factor Inhibitors and the Risk of Aortic Aneurysm and Aortic Dissection.
    Wu CW; Huang HY; Lin SY; Wang CC; Huang CF; Wu IH
    JAMA Netw Open; 2024 Mar; 7(3):e240940. PubMed ID: 38436956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Tyrosine Kinase Inhibitors and Survival and Cardiovascular Outcomes of Patients With Non-Small Cell Lung Cancer in Taiwan.
    Chang WT; Lin HW; Chang TC; Lin SH; Li YH
    JAMA Netw Open; 2023 May; 6(5):e2313824. PubMed ID: 37195663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
    Vano YA; Elaidi R; Bennamoun M; Chevreau C; Borchiellini D; Pannier D; Maillet D; Gross-Goupil M; Tournigand C; Laguerre B; Barthélémy P; Coquan E; Gravis G; Houede N; Cancel M; Huillard O; Beuzeboc P; Fournier L; Méjean A; Cathelineau X; Doumerc N; Paparel P; Bernhard JC; de la Taille A; Bensalah K; Tricard T; Waeckel T; Pignot G; Braychenko E; Caruso S; Sun CM; Verkarre V; Lacroix G; Moreira M; Meylan M; Bougouïn A; Phan L; Thibault-Carpentier C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C; Oudard S
    Lancet Oncol; 2022 May; 23(5):612-624. PubMed ID: 35390339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors.
    Yuan A; Kurtz SL; Barysauskas CM; Pilotte AP; Wagner AJ; Treister NS
    Oral Oncol; 2015 Nov; 51(11):1026-1033. PubMed ID: 26403941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection.
    Gopalakrishnan C; Bykov K; Fischer MA; Connolly JG; Gagne JJ; Fralick M
    JAMA Intern Med; 2020 Dec; 180(12):1596-1605. PubMed ID: 32897307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular Endothelial Growth Factor Receptor Inhibitors Impair Left Ventricular Diastolic Functions.
    Yokoyama H; Shioyama W; Shintani T; Maeda S; Hirobe S; Maeda M; Sakata Y; Fujio Y
    Int Heart J; 2021; 62(6):1297-1304. PubMed ID: 34853223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    van Cann T; Loyson T; Verbiest A; Clement PM; Bechter O; Willems L; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Debruyne PR; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
    Support Care Cancer; 2018 Mar; 26(3):869-878. PubMed ID: 28963584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
    Koo DH; Park I; Ahn JH; Lee DH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Lee JL
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):339-47. PubMed ID: 26687171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of early response to first-line VEGFR-TKI in patients with metastatic renal cell carcinoma on survival: A multi-institutional retrospective study.
    Sobu R; Numakura K; Naito S; Hatakeyama S; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Obara W; Ohyama C; Tsuchiya N; Habuchi T
    Cancer Med; 2023 Feb; 12(4):4100-4109. PubMed ID: 36200612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.
    Sakharkar P; Kurup S; Deb S; Assaad K; Gesinski D; Gayle EJ
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study.
    Goldman A; Bomze D; Dankner R; Fourey D; Boursi B; Arad M; Maor E
    Target Oncol; 2021 Jul; 16(4):471-483. PubMed ID: 33970401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Ghatalia P; Morgan CJ; Je Y; Nguyen PL; Trinh QD; Choueiri TK; Sonpavde G
    Crit Rev Oncol Hematol; 2015 May; 94(2):228-37. PubMed ID: 25577572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.